AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36958365 — intervention group
Group type: EXPERIMENTAL
Intervention: ART started before 2015
Number of subjects: 206891
Study 36958365 — intervention group
Group type: EXPERIMENTAL
Intervention: ART started after 2015
Number of subjects: 206891
Study 36958365 — intervention group
Group type: EXPERIMENTAL
Intervention: ART started before 2015 with CD4 < 49 cells/μL
Number of subjects: 206891
Study 36958365 — intervention group
Group type: EXPERIMENTAL
Intervention: ART started after 2015 with CD4 < 49 cells/μL
Number of subjects: 206891
Study 36958365 — intervention group
Group type: EXPERIMENTAL
Intervention: ART started before 2015 with CD4 ≥ 500 cells/μL
Number of subjects: 206891
Study 36958365 — intervention group
Group type: EXPERIMENTAL
Intervention: ART started after 2015 with CD4 ≥ 500 cells/μL
Number of subjects: 206891
Study 36958363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calorie and protein targets (6 kcal/kg per day and 0.2-0.4 g/kg per day protein)
Number of subjects: 3044
Study 36958363 — intervention group
Group type: COMPARATOR
Intervention: Standard calorie and protein targets (25 kcal/kg per day and 1.0-1.3 g/kg per day protein)
Number of subjects: 3044
Study 36958363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calorie and protein targets
Number of subjects: 3044
Study 36958363 — intervention group
Group type: COMPARATOR
Intervention: Standard calorie and protein targets
Number of subjects: 3044
Study 36958391 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Left Ventricular Restoration (AccuCinch System)
Number of subjects: 51
Study 36958470 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 100 mg every 2 weeks
Number of subjects: 0
Study 36958470 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 0
Study 36958470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36958479 — intervention group
Group type: EXPERIMENTAL
Intervention: Venefit (Closurefast)
Number of subjects: 172
Study 36958479 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency Induced Thermal Therapy (RFITT)
Number of subjects: 172
Study 36958479 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous Radiofrequency (EVRF)
Number of subjects: 172
Study 36958479 — intervention group
Group type: COMPARATOR
Intervention: Venefit
Number of subjects: 172
Study 36958479 — intervention group
Group type: COMPARATOR
Intervention: RFITT
Number of subjects: 172
Study 36958479 — intervention group
Group type: COMPARATOR
Intervention: EVRF
Number of subjects: 172
Study 36958668 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck MFI in the Recovered group
Number of subjects: 97
Study 36958668 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg MFI in the Mild group
Number of subjects: 97
Study 36958668 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic Injury Distress Scale (TIDS) and neck MFI at 1-week postinjury
Number of subjects: 97
Study 36958668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity torques
Number of subjects: 97
Study 36958702 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills TO Manage Pain (STOMP) intervention, a 12-week program including group sessions, one-on-one pain self-management sessions, and peer leaders.
Number of subjects: 280
Study 36958702 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group).
Number of subjects: 280
Study 36958720 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 22
Study 36958720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 36958740 — intervention group
Group type: EXPERIMENTAL
Intervention: Kilkari mobile messaging programme
Number of subjects: 10000000
Study 36958766 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg two times per day
Number of subjects: 816
Study 36958766 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg two times per day
Number of subjects: 816
Study 36958766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 816
Study 36958766 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every 2 weeks
Number of subjects: 816
Study 36958766 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (AEs) with tofacitinib 5 mg
Number of subjects: 816
Study 36958766 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (AEs) with tofacitinib 10 mg
Number of subjects: 816
Study 36958766 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of treatment
Number of subjects: 816
Study 36958766 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal disease activity (MDA) achievement
Number of subjects: 816
Study 36958777 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational longitudinal registry data collection
Number of subjects: 500
Study 36958792 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) for 2 hours
Number of subjects: 108
Study 36958792 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 108
Study 36958796 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg every 4 months through month 20)
Number of subjects: 188
Study 36958796 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (2 mg/kg/day, tapered after month 24)
Number of subjects: 188
Study 36958940 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma ferritin (˃55.7 ng/mL) and high triglyceride (˃1.9 mmoL/L)
Number of subjects: 2071
Study 36958940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin levels
Number of subjects: 2071
Study 36958940 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride levels
Number of subjects: 2071
Study 36958940 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride as a mediator
Number of subjects: 2071
Study 36958969 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet group (MDG, n=59)
Number of subjects: 180
Study 36958969 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean lifestyle group (MLG, n=59)
Number of subjects: 180
Study 36958969 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (SCG, n=62)
Number of subjects: 180
Study 36958977 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered stretching exercises
Number of subjects: 100
Study 36958977 — intervention group
Group type: COMPARATOR
Intervention: Motor control exercises
Number of subjects: 100
Study 36958998 — intervention group
Group type: EXPERIMENTAL
Intervention: d-serine 80 mg/kg
Number of subjects: 45
Study 36958998 — intervention group
Group type: EXPERIMENTAL
Intervention: d-serine 100 mg/kg
Number of subjects: 45
Study 36958998 — intervention group
Group type: EXPERIMENTAL
Intervention: d-serine 120 mg/kg
Number of subjects: 45
Study 36958998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 36959289 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of inflammation and coagulation
Number of subjects: 0
Study 36959289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoproteins
Number of subjects: 0
Study 36959289 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36959430 — intervention group
Group type: EXPERIMENTAL
Intervention: DO-MoST (patient-centered, motivational approach to shared decision making)
Number of subjects: 20
Study 36959430 — intervention group
Group type: EXPERIMENTAL
Intervention: DO-MoST
Number of subjects: 20
Study 36959540 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 weeks external beam radiotherapy (EBRT) and 3 years androgen deprivation therapy (ADT) with one concurrent cycle of systemic treatment (three, six, or nine GBq)
Number of subjects: 0
Study 36959584 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical, laboratory, and imaging biomarkers assessment in SMuRF-less patients
Number of subjects: 0
Study 36959584 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive transthoracic echocardiographic assessment
Number of subjects: 0
Study 36959584 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic parameters assessment using the SYNTAX score
Number of subjects: 0
Study 36959584 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable linear and logistic regression models
Number of subjects: 0
Study 36959613 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardio-oncology rehabilitation (CORE) using a telerehabilitation approach for 12 weeks
Number of subjects: 11
Study 36959613 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based CORE intervention
Number of subjects: 11
Study 36959618 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training (RMT)
Number of subjects: 0
Study 36959618 — intervention group
Group type: COMPARATOR
Intervention: Sham-Control (non-therapeutic resistance RMT)
Number of subjects: 0
Study 36959624 — intervention group
Group type: EXPERIMENTAL
Intervention: Active school transport (AST)
Number of subjects: 1070
Study 36959634 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron group (micronutrient powder with 12.5 mg of iron daily)
Number of subjects: 860
Study 36959634 — intervention group
Group type: COMPARATOR
Intervention: Noniron group (micronutrient powder without iron)
Number of subjects: 860
Study 36959636 — intervention group
Group type: EXPERIMENTAL
Intervention: GloveCare (non-sterile gloves plus hand hygiene)
Number of subjects: 750
Study 36959636 — intervention group
Group type: COMPARATOR
Intervention: Standard care (hand hygiene alone)
Number of subjects: 750
Study 36959636 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove compliance
Number of subjects: 750
Study 36959636 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset infections (LOI)
Number of subjects: 750
Study 36959658 — intervention group
Group type: EXPERIMENTAL
Intervention: Perirenal fat modification (PFM) intervention using focused power ultrasound (FPU)
Number of subjects: 200
Study 36959658 — intervention group
Group type: COMPARATOR
Intervention: Sham-procedure
Number of subjects: 200
Study 36959664 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic salpingectomy at hysterectomy
Number of subjects: 0
Study 36959672 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous leukocyte- and platelet-rich fibrin (L-PRF)
Number of subjects: 0
Study 36959672 — intervention group
Group type: COMPARATOR
Intervention: Commercially available fibrin sealants
Number of subjects: 0
Study 36959672 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF
Number of subjects: 0
Study 36959672 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF and commercially available fibrin sealants
Number of subjects: 0
Study 36959874 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatry
Number of subjects: 35
Study 36959874 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable antipsychotics (LAIs)
Number of subjects: 35
Study 36959874 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from LAIs to oral antipsychotic medications
Number of subjects: 35
Study 36959874 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from shorter to longer injection interval LAIs
Number of subjects: 35
Study 36959874 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatry services
Number of subjects: 35
Study 36959953 — intervention group
Group type: EXPERIMENTAL
Intervention: Creating Affiliations, Learning, and Mindfulness (CALM) for IVF
Number of subjects: 76
Study 36959953 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study 36959966 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine E3G monitoring
Number of subjects: 30
Study 36959966 — intervention group
Group type: COMPARATOR
Intervention: Serum E2 monitoring
Number of subjects: 30
Study 36959966 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched daily samples of urine E3G and serum E2
Number of subjects: 30
Study 36960054 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001 + nivolumab
Number of subjects: 12
Study 36960087 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 genomic sequencing performed locally for outbreak cases
Number of subjects: 59
Study 36960087 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 genomic sequencing
Number of subjects: 59
Study 36960471 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasso logistics regression (LLR) model
Number of subjects: 3392
Study 36960471 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest (RF) model
Number of subjects: 3392
Study 36960471 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme gradient boosting (XGBoost) model
Number of subjects: 3392
Study 36960471 — intervention group
Group type: COMPARATOR
Intervention: Reference AKICS score
Number of subjects: 3392
Study 36960538 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan (VPZ) 20 mg
Number of subjects: 340
Study 36960538 — intervention group
Group type: COMPARATOR
Intervention: Proton Pump Inhibitors (PPI) - Lansoprazole 30 mg or Esomeprazole 20 mg
Number of subjects: 340
Study 36960716 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket wash (500 mL antibiotic solution) and postoperative antibiotics for 3 days along with standard prophylactic measures (chlorhexidine skin preparation, intravenous antibiotics, and TYRX-a antibiotic envelope)
Number of subjects: 1010
Study 36960716 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylactic measures (chlorhexidine skin preparation, intravenous antibiotics, and TYRX-a antibiotic envelope)
Number of subjects: 1010
Study 36960730 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous epicardial substrate ablation with electroanatomical mapping
Number of subjects: 159
Study 36960730 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous epicardial substrate ablation
Number of subjects: 159
Study 36960762 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove Rehabilitation Application for Stroke Patients (GRASP) virtual reality home exercise program (HEP), used 4 times per week for 8 weeks.
Number of subjects: 0
Study 36960762 — intervention group
Group type: COMPARATOR
Intervention: Usual and customary care controls, details not specified.
Number of subjects: 0
Study 36960766 — intervention group
Group type: EXPERIMENTAL
Intervention: Same day discharge (SDD)
Number of subjects: 7181
Study 36960766 — intervention group
Group type: COMPARATOR
Intervention: Overnight observation
Number of subjects: 7181
Study 36960779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative enteral nutrition feeding (100 kcal/100 mL at 10-20 mL/h)
Number of subjects: 28
Study 36960779 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 28
Study 36961017 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine for 12 weeks
Number of subjects: 438
Study 36961086 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial Aneurysms in Patients with ADPKD
Number of subjects: 0
Study 36961086 — intervention group
Group type: COMPARATOR
Intervention: General Population
Number of subjects: 0
Study 36961220 — intervention group
Group type: EXPERIMENTAL
Intervention: Core decompression with autologous osteoblastic cell transplantation (5 mL with 20 x 10^6 cells/mL)
Number of subjects: 54
Study 36961220 — intervention group
Group type: COMPARATOR
Intervention: Core decompression with placebo (5 mL of solution without cells)
Number of subjects: 54
Study 36961220 — intervention group
Group type: EXPERIMENTAL
Intervention: Core decompression with autologous osteoblastic cell transplantation
Number of subjects: 54
Study 36961220 — intervention group
Group type: COMPARATOR
Intervention: Core decompression with placebo
Number of subjects: 54
Study 36961228 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36961347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo effects (conditioning and verbal suggestions)
Number of subjects: 37
Study 36961347 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning and verbal suggestions
Number of subjects: 37
Study 36961347 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analyses (type of sensory stimulation)
Number of subjects: 37
Study 36961347 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of bias
Number of subjects: 37
Study 36961348 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnometry-Assisted Respiratory Training (CART) to raise P co2
Number of subjects: 120
Study 36961348 — intervention group
Group type: COMPARATOR
Intervention: Feedback to slow respiratory rate (SLOW)
Number of subjects: 120
Study 36961410 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical cannabis use after certification
Number of subjects: 0
Study 36961591 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (NSPT) with patients having major stress levels
Number of subjects: 90
Study 36961591 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (NSPT) with patients having avoidance coping strategies
Number of subjects: 90
Study 36961596 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal flexibility (VF) measured across social stressor tasks
Number of subjects: 151
Study 36961596 — intervention group
Group type: COMPARATOR
Intervention: Children meeting diagnostic criteria for social anxiety disorder
Number of subjects: 151
Study 36961650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ari 2MRTU 960 (960 mg) every 56 ± 2 days (four injections scheduled)
Number of subjects: 266
Study 36961650 — intervention group
Group type: COMPARATOR
Intervention: AOM 400 (400 mg) every 28 ± 2 days (eight injections scheduled)
Number of subjects: 266
Study 36961650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ari 2MRTU 960
Number of subjects: 266
Study 36961650 — intervention group
Group type: COMPARATOR
Intervention: AOM 400
Number of subjects: 266
Study 36961653 — intervention group
Group type: EXPERIMENTAL
Intervention: Setmelanotide treatment
Number of subjects: 19
Study 36961654 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab 1.5 mg/kg weekly
Number of subjects: 413
Study 36961654 — intervention group
Group type: COMPARATOR
Intervention: Real-world physician's choice of therapy (RWPC)
Number of subjects: 413
Study 36961726 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy (PBT)
Number of subjects: 500
Study 36962125 — intervention group
Group type: EXPERIMENTAL
Intervention: Andilaye intervention
Number of subjects: 1589
Study 36962125 — intervention group
Group type: COMPARATOR
Intervention: Standard of care sanitation and hygiene programming (CLTSH)
Number of subjects: 1589
Study 36962306 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children-for Caregivers (ICC-C)
Number of subjects: 156
Study 36962504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramadan fasting
Number of subjects: 913
Study 36962510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track (FT) service delivery model
Number of subjects: 905
Study 36962510 — intervention group
Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 905
Study 36962514 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC with P4P
Number of subjects: 818
Study 36962514 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC without P4P
Number of subjects: 818
Study 36962514 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC
Number of subjects: 818
Study 36962514 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term OAT (>3 months)
Number of subjects: 818
Study 36962514 — intervention group
Group type: COMPARATOR
Intervention: SATC (treatment as usual)
Number of subjects: 818
Study 36962656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfer only
Number of subjects: 0
Study 36962656 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cups plus cash transfer
Number of subjects: 0
Study 36962656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup only
Number of subjects: 0
Study 36962656 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 36962671 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO eTB RecMap
Number of subjects: 244
Study 36962671 — intervention group
Group type: COMPARATOR
Intervention: Conventional WHO website
Number of subjects: 244
Study 36962680 — intervention group
Group type: EXPERIMENTAL
Intervention: Plan and commit intervention
Number of subjects: 1478
Study 36962680 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care intervention
Number of subjects: 1478
Study 36962680 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (control)
Number of subjects: 1478
Study 36962700 — intervention group
Group type: EXPERIMENTAL
Intervention: LIVE intervention (educational 3D world)
Number of subjects: 211
Study 36962700 — intervention group
Group type: COMPARATOR
Intervention: Control website (diabetes self-management education and support)
Number of subjects: 211
Study 36962706 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal artesunate (RAS) pre-referral treatment
Number of subjects: 0
Study 36962706 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Access to Rectal Artesunate for Malaria (CARAMAL) project
Number of subjects: 0
Study 36962786 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly follow-up
Number of subjects: 0
Study 36962786 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (weekly follow-up)
Number of subjects: 0
Study 36962830 — intervention group
Group type: EXPERIMENTAL
Intervention: IMARA-SA intervention group
Number of subjects: 59
Study 36962830 — intervention group
Group type: COMPARATOR
Intervention: Health promotion control group
Number of subjects: 59
Study 36962838 — intervention group
Group type: EXPERIMENTAL
Intervention: 20μg/20μg (fractional dose) of BNT162b2
Number of subjects: 145
Study 36962838 — intervention group
Group type: COMPARATOR
Intervention: 30μg/30μg (full dose) of BNT162b2
Number of subjects: 145
Study 36962838 — intervention group
Group type: COMPARATOR
Intervention: Comparison of reduced dose to full dose
Number of subjects: 145
Study 36962838 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall safety
Number of subjects: 145
Study 36962857 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive focal drug administration (RFDA)
Number of subjects: 6276
Study 36962857 — intervention group
Group type: COMPARATOR
Intervention: Reactive focal test and treat (RFTAT)
Number of subjects: 6276
Study 36962912 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Quality of Life (LQoL) group
Number of subjects: 3998
Study 36962912 — intervention group
Group type: COMPARATOR
Intervention: High Quality of Life (HQoL) group
Number of subjects: 3998